SearchSearach Website
Close Searach

Search Website

A

Larger Smaller

A

Living Well With Low Vision Sponsored by Prevent Blindness
  • News
  • Clinical Trials
  • Resources
  • Free Books
  • Stories
  • About
  • Contact
  • Donate
Skip to content
Skip to content

Living Well With Low Vision

  • News
  • Clinical Trials
  • Resources
  • Free Books
  • Stories
  • About
  • Contact
  • Donate

News & Archive Categories

    Gene therapy treatment for wet AMD shows positive results

    Posted on August 11, 2020December 11, 2020 by Dan Roberts
  • August 11, 2020

    Gene therapy treatment for wet AMD shows positive results

    (Updated 12/11/2020) REGENXBIO, Inc. has reported positive one year data from patients in Cohorts 4 and 5 of the Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). As reported here in June 2017, RGX-314 is being developed as a one-time sub-retinal injection for wet AMD. It would be […]

      Also posted in
    • Latest News
    • Research and Developments
  • AMD associated with greater COVID mortality

    Posted on August 3, 2020August 3, 2020 by Dan Roberts
  • August 3, 2020

    AMD associated with greater COVID mortality

    The human’s natural immune system (called complement) has been found to be associated with the severity of COVID disease in people with age-related macular degeneration (AMD), according to a new study published in Nature Medicine. A hyperactive complement system is known to be directly related to development of AMD. In a retrospective observational study of […]

      Also posted in
    • Latest News
    • Research and Developments
  • New Drug For Wet AMD Should Be Used With Caution

    Posted on July 22, 2020July 24, 2020 by Dan Roberts
  • July 22, 2020

    New Drug For Wet AMD Should Be Used With Caution

    Beovu (brolucizumab) for wet AMD is the newest anti-VEGF drug on the market. It has been shown to be an effective and long-lasting inhibitor of blood vessel development (neovascularization) in the retina. The drug’s manufacturer has, however, been recently investigating incidences of severe intraocular inflammation (vasculitis) and retinal artery occlusion that were reported after their product […]

      Also posted in
    • Latest News
    • Research and Developments
    • Therapies, Treatments, and Procedures
  • Port Delivery System for Wet AMD May Soon Be in Clinics

    Posted on July 22, 2020 by Dan Roberts
  • July 22, 2020

    Port Delivery System for Wet AMD May Soon Be in Clinics

    We reported here in October 2019 that Genentech had reported good Phase 2 trial results examining the use of their unique alternative to intravitreal injections. The Port Delivery System (PDS) is a tiny refillable implant that provides patients affected by wet (neovascular) age-related macular degeneration with continuous delivery of Lucentis as necessary. The company has […]

      Also posted in
    • Daily Living
    • Research and Developments
  • Are some patients with CNV unresponsive to anti-VEGF?

    Posted on June 14, 2020July 12, 2020 by Dan Roberts
  • June 14, 2020

    Are some patients with CNV unresponsive to anti-VEGF?

    Since 2004, anti-VEGF drug injections have been shown to be highly effective in suppressing choroidal neovascularization (CNV) in the retinas of people with wet age-related macular degeneration and diabetic retinopathy. They have also been shown to suppress further CNV for as long as 12 weeks, depending upon the drug being used and the disease state […]

      Also posted in
    • Latest News
    • Therapies, Treatments, and Procedures
  • Telehealth usage increases during COVID-19

    Posted on June 14, 2020 by Dan Roberts
  • June 14, 2020

    Telehealth usage increases during COVID-19

    A survey of 2,000 adults in the U.S. has shown that 42% have used telehealth services in place of their regular in-person visits to eye clinics since the beginning of the COVID-19 pandemic in March 2020. Telehealth is a service made available by way of telecommunication devices like computers and smart phones. Using this recent […]

      Also posted in
    • Daily Living
    • Latest News
  • OpRegen® for geographic atrophy maintains positive results

    Posted on June 6, 2020 by Dan Roberts
  • June 6, 2020

    OpRegen® for geographic atrophy maintains positive results

    Lineage Cell Therapeutics (originally BioTime, Inc.) has announced positive results with its experimental OpRegen® therapy for geographic atrophy (GA), the advanced stage of dry macular degeneration. The company began enrolling and treating U.S.-based patients in 2017 under David S. Boyer, M.D. (Retina-Vitreous Associates Medical Group, Los Angeles) and H. Richard McDonald, M.D., (West Coast Retina […]

      Also posted in
    • Latest News
    • Research and Developments
  • Experimental stem cell treatment continues to maintain vision

    Posted on June 5, 2020June 5, 2020 by Dan Roberts
  • June 5, 2020

    Experimental stem cell treatment continues to maintain vision

    A procedure reported here in March 2018 has been shown to continue being a safe and effective method for introducing stem cells into the retina. Eye researcher Professor Pete Coffey, who founded the London Project over a decade ago, has confirmed that two study patients have maintained improvements in their vision five years after surgery. […]

      Also posted in
    • Latest News
    • Research and Developments
  • Vision loss influences sound perception

    Posted on June 4, 2020June 5, 2020 by Dan Roberts
  • June 4, 2020

    Vision loss influences sound perception

    People with severe vision loss can less accurately judge the distance of nearby sounds, potentially putting them more at risk of injury, according to new research published in the journal Scientific Reports. Researchers from Anglia Ruskin University’s Vision and Eye Research Institute (VERI) tested participants with different levels of vision loss, presenting them with speech, music […]

      Also posted in
    • Daily Living
    • Latest News
  • Eye Injections for Wet AMD May Soon Be Unnecessary

    Posted on May 27, 2020 by Dan Roberts
  • May 27, 2020

    Eye Injections for Wet AMD May Soon Be Unnecessary

    Genentech has announced positive top line results from its Phase III Archway study, evaluating Port Delivery System (PDS) with Lucentis (ranibizumab) in people living with wet (neovascular)AMD. PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of Lucentis over a period of months. […]

      Also posted in
    • Latest News
    • Research and Developments
    • Therapies, Treatments, and Procedures
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 56
  • Next Page »
Some Like it Neat, by Alex Vasquez
© All Rights Reserved
Footer Content Right

Receive News and Updates


 

We look to your generosity to support Prevent Blindness and keep our resources up to date.

Donate Now
  • Facebook
  • Twitter
Privacy Policy
Prevent Blindness

© 2018 Prevent Blindness. All rights reserved.